Semaglutide and tirzepatide produce real, meaningful weight loss. But when the medication stops, or when it's used without a deeper plan, most patients regain the weight and the metabolic damage that came with it. RCOMPx is built around that reality.
The data we don't ignore
≈ 2 in 3
of patients regain most lost weight within a year of stopping GLP-1s
STEP-1 extension trial, NEJM 2022
−9.4%
average body weight regained at 1 year after semaglutide discontinuation
Wilding et al., Diabetes Obes Metab 2022
> 1 billion
people worldwide now live with obesity, a tripling since 1990
World Obesity Federation, 2024
< 5%
of obesity is actually a willpower problem, the rest is biology, hormones and environment
Endocrine Society consensus
Sources are illustrative of the published literature; exact figures vary by study population. The clinical pattern, significant relapse without behavioral and metabolic support, is consistent.
The RCOMP answer
Medication is one tool. The RCOMP program, pioneered by Dr. Zahraa Sater, surrounds it with the diagnostics and behavioral work needed to make results last beyond the prescription.
Insulin resistance, thyroid, cortisol, inflammation, sleep, micronutrients, investigated, not assumed.
Personalized nutrition, movement and a GLP-1 strategy with a planned independence roadmap, not indefinite use.
Clinical hypnotherapy (RTT) addresses the emotional and behavioral drivers most weight programs never touch.
See how RCOMPx structures the RCOMP program inside your clinic, from intake to independence.